Why the study?
Does adriamycin-based chemotherapy alter myocardial glucose metabolism as measured by FDG-PET in lymphoma patients?
Population
18 lymphoma patients treated with adriamycin-based chemotherapy
Comparison
Adriamycin-based chemotherapy vs Baseline (pre-therapy) FDG-PET scan
Design
Cohort
Authors
Loading...
Variable FDG-PET changes after adriamycin may signal early cardiotoxicity risk; hypothesis-generating and should not yet change practice.
Does adriamycin-based chemotherapy alter myocardial glucose metabolism as measured by FDG-PET in lymphoma patients?
Adriamycin-based chemotherapy induces variable early changes in myocardial glucose metabolism detectable by FDG-PET, which warrants further investigation as a potential early marker of cardiotoxicity.
Chaitanya Borde (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: